I discuss the timeline of Ratify and Quantum. Was this an ethical trial? Is it sufficient to say a trial is ethical because 50% of participants get something?

The drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates

Are the results from Luis Diaz as good as touted. What trial should they do going forward?

A 100% CR rate in Stage II and III rectal cancer??

My take on the standing ovation for DESTINY Breast 04

Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

I break down Richardson, et al. NEJM DETERMINATION

Transplanters are determined to keep going, should they be?

Watch the videos b/c I have lots of great visuals

My ASCO Coverage continues

The second paper from #ASCO2022 #ASCO22 that I break down

This is one of the most technical papers I breakdown on the channel

CT DNA used to omit chemo in Stage II colon cancer

Read the book Malignant if you learn from this

Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint

No OS

Bad crossover

Lots to discuss here

I will be covering all the major ASCO papers on @PlenarySession

Subscribe to my substack https://vinayprasadmdmph.substack.com/

I am joined by Dr. Katie Sharff, infectious disease doc, to discuss two of her papers on myocarditis after COVID-19 vaccination.

https://doi.org/10.1016/j.amjcard.2022.02.039

https://doi.org/10.1101/2021.12.21.21268209

I get back to my roots; I explain surrogate validation and a new JCO paper from the FDA authors on EFS and OS in AML. You won't want to miss it

In this episode I dissect a test negative case control trial; I talk about a famous pancreas cancer study and I revisit the failure of Myeloma trialists